Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LITT and Lomustine in Recurrent Glioblastoma
NCT03022578Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2017
- Primary completion
- Feb 2021
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Disease Control Rate at 6 Months. Started Nov 2017; status: terminated.
Beyond the preview
Go deeper on NCT03022578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03022578.